Protopic

Legal status and availability in the UK

In our online pharmacy, Protopic is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Basic Protopic information

• INN (international nonproprietary name): Tacrolimus
• Brand names available in the United Kingdom: Protopic; generic tacrolimus ointment may also be available.
• ATC code: D11AH01 — tacrolimus (topical calcineurin inhibitor)
• Forms and strengths: ointment 0.03% (for children ≥2 years and adults) and ointment 0.1% (for adults and adolescents ≥16 years); common tube sizes include 30g and 60g.
• Manufacturers in the United Kingdom: Astellas Pharma (originator); generic manufacturers may also supply.
• OTC / Rx classification: Prescription only (Rx); not over-the-counter.

Clinical effectiveness in the UK

Concerned whether tacrolimus works as well as topical steroids in real NHS practice?

In NHS settings tacrolimus ointment is typically used when topical corticosteroids are unsuitable, for example for facial or eyelid eczema, or where long‑term steroid use risks skin atrophy.

Patients often see meaningful reductions in itch, sleep disturbance and Dermatology Life Quality Index (DLQI) scores within 1–3 weeks of twice‑daily use of the appropriate strength.

Standard dosing forms used in the NHS include 0.03% for children aged two and over and either 0.03% or 0.1% for adults, with 0.1% generally reserved for older adolescents and adults requiring greater potency.

Tacrolimus can give similar control to mid‑potency steroids on small, localised areas while offering a lower risk of skin thinning.

Adherence is frequently affected by initial burning or stinging sensations; pharmacist counselling and NHS leaflets are effective at improving continuation.

NHS electronic prescription services and repeat prescribing pathways facilitate maintenance regimens of once or twice weekly application to previous lesions to reduce relapse.

Many UK patients prefer a steroid‑free maintenance strategy for visible areas, and clear follow‑up routes via NHS 111, dermatology clinics or community pharmacists are important to maintain adherence and safety.

Indications and expanded uses

Wondering what tacrolimus is officially licensed for and when clinicians might consider off‑label use?

Licensed UK indications cover moderate‑to‑severe atopic dermatitis in adults and children from age two, and tacrolimus ointment is prescription‑only.

In UK practice tacrolimus is typically reserved for steroid‑intolerant sites such as the face, neck and flexures, cases of steroid‑phobia, long‑term maintenance to prevent flares, and wherever skin atrophy risk must be minimised.

Common off‑label uses in some dermatology clinics and private practice include targeted use for chronic prurigo nodularis lesions or steroid‑refractory perioral dermatitis, although the supporting evidence base is limited and specialist oversight is advised.

Tacrolimus is not approved for children under two years, for application to mucous membranes, or to open wounds.

UK clinicians emphasise documented informed consent for any off‑label use and clear safety netting via NHS patient portals.

Concurrent systemic immunosuppression or significant immune compromise is considered a contraindication and should prompt discussion with secondary care dermatology or the prescribing specialist.

Composition and brand landscape

Not sure which brands or tube sizes you might see on a prescription?

The active ingredient is tacrolimus, a topical calcineurin inhibitor supplied as an ointment in two licensed concentrations: 0.03% and 0.1%.

The original brand is Protopic from Astellas Pharma; generic tacrolimus ointments may also be available.

ATC classification is D11AH01 — topical tacrolimus under dermatologicals.

Packaging commonly uses 30g or 60g tubes and strengths are chosen by age: 0.03% for children aged two and over and adults, and 0.1% for adults and adolescents aged 16 and over.

Pharmacies dispense Protopic and generics on prescription.

Local formularies affect which brands are routinely prescribed.

Patient communications should clarify that the correct pharmaceutical form is an ointment, even though patients may call it a “cream”.

Contraindications and special precautions

• Absolute — Known hypersensitivity to tacrolimus or ointment excipients (mineral oil, paraffin); active skin infections such as herpes simplex, varicella or bacterial infection; patients with compromised immune systems (post‑transplant, uncontrolled HIV, on systemic immunosuppressants).
• Relative — History or family history of skin cancer or premalignant lesions; use with caution on very thin or widely broken skin; avoid mucous membranes, open wounds and occlusive dressings.
• Daily-life advice — Minimise UV exposure and avoid sunbeds; use sunscreen and protective clothing; report persistent irritation or secondary infection to a GP or dermatologist.

Pregnancy and breastfeeding should prompt specialist advice and use only when benefits outweigh risks.

MHRA guidance and NHS counselling stress monitoring for persistent irritation and secondary infection, and careful use in the elderly where skin barrier and thickness are altered.

There is no established driving impairment, and interactions with alcohol are limited to occasional transient flushing reported by some patients.

Dosage guidelines (NHS‑aligned)

How should tacrolimus be started, and when is maintenance appropriate?

Apply a thin layer of the ointment to affected areas twice daily until clear, typically within one to three weeks, then discontinue.

For maintenance and prevention of relapse, apply once or twice weekly to previously affected sites as per NHS practice to reduce recurrence.

Strength selection follows age guidance: 0.03% for children aged two years and over and adults; 0.1% for adults and adolescents aged 16 years and over.

No routine dose adjustment is required for the elderly or for hepatic or renal impairment because systemic absorption is minimal, but exercise caution if skin is widely broken or very thin.

If a dose is missed apply when remembered but do not double the next application.

Overdose is rare with topical use; seek medical advice if significant accidental ingestion occurs.

Interactions overview

Worried about drug interactions if you are on other medicines?

Topical tacrolimus has minimal systemic exposure so clinically significant drug–drug interactions are uncommon.

Patients must not confuse topical tacrolimus with systemic tacrolimus formulations such as Prograf or Advagraf, which have many important interactions and are used for systemic immunosuppression.

Concurrent potent CYP3A4 inhibitors are only relevant if significant systemic absorption occurs, such as with large‑area application to widely broken skin — this is rare.

Additive immunosuppression is a concern when topical tacrolimus is used alongside systemic immunosuppressants; combined therapy should be avoided without specialist oversight.

Pharmacists should alert prescribers via NHS electronic prescription notes when patients are on systemic immunosuppressants, antiretrovirals or chemotherapy.

Comparable medicines and prescribing preferences

Which alternatives might a GP or dermatologist consider instead of tacrolimus?

Topical corticosteroids remain first‑line treatment for most flares, with tacrolimus used where steroids are undesirable due to atrophy risk or for maintenance on sensitive sites.

Pimecrolimus cream (Elidel) is mechanistically similar and often chosen for milder paediatric facial eczema, while tacrolimus 0.1% provides greater potency for adults.

Pros of tacrolimus include steroid‑free long‑term maintenance suitability for thin skin areas; cons include transient burning/stinging at initiation, and labelled immunosuppression cautions.

Shared decision‑making in the UK commonly balances visible area management, prior steroid side effects and patient preference alongside local formulary guidance.

Frequently asked questions

• Is Protopic a steroid? No. Tacrolimus is a calcineurin inhibitor ointment and does not cause steroid‑related skin thinning.
• Can my child use it? Yes for children aged two years and older using 0.03% ointment; use in children under two is not approved.
• How long until it works? Many patients see improvement within one to three weeks; initial transient burning is common and usually settles.
• Can I use it on my face or eyelids? Yes — tacrolimus is often chosen for these sensitive areas to avoid steroid atrophy, but avoid mucous membranes and open wounds.

For worsening infection, severe irritation or systemic symptoms contact your GP, NHS 111 or local dermatology services as advised on the NHS website.

Guidelines for proper use and pharmacist counselling

Want a simple checklist to take away from the pharmacy?

• Explain the formulation is an ointment and the strength appropriate for the patient’s age (0.03% for children ≥2; 0.1% for adults/adolescents ≥16).
• Apply a thin layer twice daily to affected areas until clear, then use once or twice weekly for maintenance to prevent relapse.
• Advise on transient burning at initiation; emollients can be used but advise timing (apply emollient first if required).
• Warn against use on infected skin, mucous membranes, open wounds or under occlusive dressings and against combining with systemic immunosuppression without specialist input.
• Storage: store below 25°C, do not freeze, keep tube tightly closed and protected from light; check expiry and follow SPC guidance.

Provide safety netting: seek GP or dermatology review for worsening infection, persistent irritation or suspected systemic signs, and document follow‑up arrangements via NHS patient portals or printed leaflets.

Delivery across the United Kingdom